A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Summary
To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.
Description
Primary Objectives * To identify early efficacy signals for SAR445877 in ICI-exposed NSCLC participants * Identify biomarkers related to the mechanism of action in SAR445877 and predictive of response/resistance in ICI-exposed NSCLC participants
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Eligibility Criteria 1. Ability to understand and willingness to sign informed consent form (ICF) prior to initiation of the study and any study procedures. 2. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SAR445877 in participants \<18 years of age, children are excluded from this study. 3. Participants with histologically documented locally advanced or metastatic NSCLC who have had disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or…
Interventions
- DrugSAR445877
Given by IV
Location
- MD Anderson Cancer CenterHouston, Texas